These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 32518675)

  • 1. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?
    Tomah S; Alkhouri N; Hamdy O
    Clin Diabetes Endocrinol; 2020; 6():9. PubMed ID: 32518675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis.
    Kuchay MS; Misra A
    Diabetes Metab Syndr; 2022 Mar; 16(3):102446. PubMed ID: 35259705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Khan FZ; Perumpail RB; Wong RJ; Ahmed A
    World J Hepatol; 2015 Aug; 7(18):2155-61. PubMed ID: 26328027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Younossi Z; Tacke F; Arrese M; Chander Sharma B; Mostafa I; Bugianesi E; Wai-Sun Wong V; Yilmaz Y; George J; Fan J; Vos MB
    Hepatology; 2019 Jun; 69(6):2672-2682. PubMed ID: 30179269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic Fatty Liver Disease in South Asia.
    Pati GK; Singh SP
    Euroasian J Hepatogastroenterol; 2016; 6(2):154-162. PubMed ID: 29201749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease: Could It Be the Next Medical Tsunami?
    Bhandari P; Sapra A; Ajmeri MS; Albers CE; Sapra D
    Cureus; 2022 Apr; 14(4):e23806. PubMed ID: 35518541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.
    Kim H; Lee DS; An TH; Park HJ; Kim WK; Bae KH; Oh KJ
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology.
    Yoon IC; Eun JR
    Yeungnam Univ J Med; 2019 May; 36(2):67-77. PubMed ID: 31620616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis.
    Sayiner M; Lam B; Golabi P; Younossi ZM
    Therap Adv Gastroenterol; 2018; 11():1756284818811508. PubMed ID: 30479664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K; Articolo A; Luthra R; Charlton M
    BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Soejima Y; Fukusato T
    World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges.
    Ahmad MI; Khan MU; Kodali S; Shetty A; Bell SM; Victor D
    J Hepatocell Carcinoma; 2022; 9():477-496. PubMed ID: 35673598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Cernea S; Onișor D
    World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.